Company intelligence / Profile preview

Chongqing Jiachen Biotechnology Ltd.

Chongqing, Chongqing Shi, China

Ownership: Private
Development stage: Other

Overview

Chongqing Jiachen Biotechnology has developed a mimogen-based therapeutic hepatitis B vaccine that has completed Phase II clinical trials in China. The company operates a large GMP-certified facility and manages over 30 drug products marketed domestically. It is also active in contract research/clinical trial management using modern EDC systems.

Therapeutic areas: Infectious Diseases
Modalities: Therapeutic vaccinesLikely small molecules and biologics based on manufacturing scope
Industry: Biotech

Drug pipeline

1 asset

therapeutic HBV vaccine

Partnerships

No major global pharma partnerships disclosed; partnered with StudyManager for EDC/CTMS solutions.Founding partners include Chongqing Beer, The Third PLA Medication University, and Chongqing University.

Beyond the preview

Go deeper on Chongqing Jiachen Biotechnology Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chongqing Jiachen Biotechnology Ltd..